🇺🇸 FDA

Intelligence · Patent portfolio

United Therapeutics Europe Patents

Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.

Patents
3,720
Expiring ≤24m
234

Quick answer

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.

Page 11 of 78

  1. US 11285169

    Methods for modulating chemotherapeutic cytotoxicity

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11285178

    Fertilized egg isolate and uses thereof

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11286467

    System and method for production of fatty acid ethanolamides

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11278572

    Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11278521

    GAS5 binding compounds, formulations, and uses thereof

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11274077

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11273214

    Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11274303

    Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11274305

    Compositions and methods for in vivo excision of HIV-1 proviral DNA

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11274163

    Ultra-stable protein ionic liquids

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11273130

    Methods of delivering a neuroprotective polypeptide to the central nervous system

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11266726

    Compositions and methods for the treatment of HER2-expressing solid tumors

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11266692

    Intracellular genomic transplant and methods of therapy

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11268096

    Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11266676

    MicroRNA in T cell activation

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11266746

    Therapeutic antitumor combination of a TLR4 ligand with other treatments

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11261152

    Inhibitors of the N-terminal domain of the androgen receptor

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11260050

    Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11254662

    2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11254667

    Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11254735

    Prevention of tissue ischemia and related methods

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11253489

    Visual cycle modulators

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11253511

    Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11248039

    Immunoglobulin single variable domain antibody against RSV prefusion F protein

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11246881

    Nanoparticle to target cancer

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11247971

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11242339

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11243213

    Kits and methods for prediction and treatment of preeclampsia

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11241436

    Autophagy inducers for treatment of CNS conditions

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11236152

    Neutralizing antibodies to HIV-1 GP41 and their use

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11235054

    Multivalent vaccine composition

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11235056

    Glycan-masked engineered outer domains of HIV-1 gp120 and their use

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11236340

    Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11236122

    Triterpene amine derivatives

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11236315

    Thermophile peptidoglycan hydrolase fusion proteins and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11236035

    Salts of treprostinil

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11234953

    Ketone bodies to protect tissues from damage by ionizing radiation

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11236161

    Chimeric antigen receptors targeting CD-19

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11236139

    Combination immunotherapy

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11236171

    Human monoclonal antibodies specific for FLT3 and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11236151

    Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11230607

    CD47 targeted therapies for the treatment of infectious disease

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11230590

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11225469

    Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11224626

    Methods of identifying bacteriophages that can infect and kill host-adapted infectious pathogenic bacteria

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11207361

    AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11207339

    Targeted cancer therapy

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11207394

    Anti-mutated KRAS T cell receptors

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.